Encorafenib

Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM) .

Product Specifications

CAS Number

[1269440-17-6]

Product Name Alternative

LGX818

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Raf

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/LGX818.html

Purity

99.93

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(OC)N[C@@H](C)CNC1=NC=CC(C2=CN(C(C)C)N=C2C3=CC(Cl)=CC(NS(=O)(C)=O)=C3F)=N1

Molecular Formula

C22H27ClFN7O4S

Molecular Weight

540.01

Precautions

H302, H315, H319, H335

References & Citations

[1]Compounds and compositions as protein kinase inhibitors . Patent WO 2011025927 A1|[2]Li Z, et al. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016 Jan 28;370 (2) :332-44.